EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes

Nathaniel J Hogrebe, Matthew Ishahak, Jeffrey R Millman

Cell Stem Cell · 2023-05 · 30 (5) · 530-548

DOI: 10.1016/j.stem.2023.04.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Stem Cell, 2023-05. Verfasst von Nathaniel J Hogrebe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, MSC 8127-057-08, 660 South Euclid Avenue, St. Lou…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Islets of Langerhans, Insulin-Secreting Cells, Pluripotent Stem Cells. Die Arbeit wurde bisher 221-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, JDRF, Washington University in St Louis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Islets of LangerhansInsulin-Secreting CellsPluripotent Stem CellsHumansCell Differentiation

Stichwörter der Autor:innen

CRISPRSC-isletsbioreactorsclinical trialscritical quality attributescryopreservationdiabetesdifferentiationdistributionencapsulationimmune toleranceinsulinpancreassafetyscale-up

Autor:innen und Institutionen

  • Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, MSC 8127-057-08, 660 South Euclid Avenue, St. Louis, MO 63130, USA. Electronic address: nhogrebe@wustl.edu.
  • Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, MSC 8127-057-08, 660 South Euclid Avenue, St. Louis, MO 63130, USA.
  • Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, MSC 8127-057-08, 660 South Euclid Avenue, St. Louis, MO 63130, USA; Department of Biomedical Engineering, Washington Un…

Förderung

  • NIDDK NIH HHS
  • JDRF
  • Washington University in St Louis
  • NIH
  • Edward Mallinckrodt, Jr. Foundation

Zitieren

APA

Hogrebe, N. J., Ishahak, M., & Millman, J. R. (2023). Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell, 30(5), 530-548. https://doi.org/10.1016/j.stem.2023.04.002

Vancouver

Hogrebe NJ, Ishahak M, Millman JR. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell. 2023;30(5):530-548. doi:10.1016/j.stem.2023.04.002

BibTeX
@article{Hogrebe2023,
  author = {Hogrebe, Nathaniel J and Ishahak, Matthew and Millman, Jeffrey R},
  title = {Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes},
  journal = {Cell Stem Cell},
  year = {2023},
  volume = {30},
  number = {5},
  pages = {530--548},
  doi = {10.1016/j.stem.2023.04.002}
}
Kostenlos starten →